Guardant Health, Inc. announced that Palmetto GBA, a Medicare administrative contractor, granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.
This decision expands the prior Medicare coverage, which was limited to Guardant Reveal testing for CRC in the early post-surgical setting. The Guardant Reveal test, running on Guardant’s Smart Liquid Biopsy platform, uses epigenomic analysis to detect circulating tumor DNA (ctDNA) as a marker of minimal residual disease (MRD).
Helmy Eltoukhy, Guardant Health chairman and co-CEO, emphasized that utilizing ctDNA testing in surveillance alongside standard monitoring can identify molecular recurrence ahead of traditional imaging. This expanded coverage makes the tissue-free test more widely available, supporting oncologists in making informed therapeutic decisions for a broader patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.